Artículos de revistas
Cheaper Faster Drug Development Validated By The Repositioning Of Drugs Against Neglected Tropical Diseases
Registro en:
Journal Of The Royal Society Interface. Royal Society Of London, v. 12, n. 104, p. - , 2015.
17425689
10.1098/rsif.2014.1289
2-s2.0-84923260810
Autor
Williams K.
Bilsland E.
Sparkes A.
Aubrey W.
Young M.
Soldatova L.N.
De Grave K.
Ramon J.
De Clare M.
Sirawaraporn W.
Oliver S.G.
King R.D.
Institución
Resumen
There is an urgent need to make drug discovery cheaper and faster. This will enable the development of treatments for diseases currently neglected for economic reasons, such as tropical and orphan diseases, and generally increase the supply of new drugs. Here, we report the Robot Scientist 'Eve' designed to make drug discovery more economical. A Robot Scientist is a laboratory automation system that uses artificial intelligence (AI) techniques to discover scientific knowledge through cycles of experimentation. Eve integrates and automates library-screening, hit-confirmation, and lead generation through cycles of quantitative structure activity relationship learning and testing. Using econometric modelling we demonstrate that the use of AI to select compounds economically outperforms standard drug screening. For further efficiency Eve uses a standardized form of assay to compute Boolean functions of compound properties. These assays can be quickly and cheaply engineered using synthetic biology, enabling more targets to be assayed for a given budget. Eve has repositioned several drugs against specific targets in parasites that cause tropical diseases. One validated discovery is that the anti-cancer compound TNP-470 is a potent inhibitor of dihydrofolate reductase from the malaria-causing parasite Plasmodium vivax. 12 104
Ioset, J.R., Chang, S., Drugs for neglected diseases initiative model of drug development for neglected diseases: Current status and future challenges (2011) Future Med. Chem., 3, pp. 1361-1371 Leslie, M., Drug developers finally take aim at a neglected disease (2011) Science, 333, pp. 933-935 Braun, M.M., Farag-El-Massah, S., Xu, K., Coté, T.R., Emergence of orphan drugs in the United States: A quantitative assessment of the first 25 years (2010) Nat. Rev. Drug Disc., 9, pp. 519-522 Pammolli, F., Magazzini, L., Riccaboni, M., The productivity crisis in pharmaceutical R&D (2011) Nat. Rev. Drug Disc., 10, pp. 428-437 Gad, S.C., (2005) Drug Discovery Handbook, , New York, NY: Wiley Martin, Y.C., (2010) Quantitative Drug Design: A Critical Introduction, , 2nd edn Boca Raton, FL: CRC Press Bernal, J.D., (1969) Science in History, 4. , Harmondsworth, UK: Penguin King, R.D., Whelan, K.E., Jones, F.M., Reiser, P.G.K., Bryant, C.H., Muggleton, S.H., Kell, D.B., Oliver, S.G., Functional genomic hypothesis generation and experimentation by a robot scientist (2004) Nature, 427, pp. 247-252 King, R.D., The automation of science (2009) Science, 324, pp. 85-89 Sparkes, A., Towards robot scientists for autonomous scientific discovery (2010) Autom. Exp., 2, pp. 1-22 Baumann, M., Baxendale, I.R., Ley, S.V., Martin, R.E., Schneider, J., Synthesis of a drug-like focused library of trisubstituted pyrrolidines using integrated flow chemistry and batch methods (2011) ACS Comb. Sci., 13, pp. 405-413 Rasmussen, C.E., Williams, C.K.I., (2006) Gaussian Processes for Machine Learning, , Cambridge, MA: The MIT Press De Grave, K., Ramon, J., De Raedt, L., Active learning for high throughput screening, pp (2008) Lecture Notes in Computer Science, 5255, pp. 185-196. , Berlin, Germany: Springer O'boyle, N.M., Banck, M., James, C.A., Morley, C., Vandermeersch, T., Hutchison, G.R., Open Babel: An open chemical toolbox (2011) J. Cheminform., 3, p. 33 Cohn, D.A., Ghahramani, Z., Jordan, M.I., Active learning with statistical models (1996) J. Artificial Intell. Res., 4, pp. 129-145 Lounkine, E., Large-scale prediction and testing of drug activity on side-effect targets (2012) Nature, 486, pp. 361-367 Vogel, H.G., Drug discovery and evaluation: Pharmacological assays (2002) Berlin, Germany: Springer Schneider, G., Virtual screening: An endless staircase (2010) Nat. Rev. Drug Disc., 9, pp. 273-276 Deutsch, D., Quantum theory, the Church-Turing principle and the universal quantum computer (1985) Proc. R. Soc. Lond. A, 400, pp. 97-117 Benenson, Y., Gil, B., Ben-Dor, U., Adar, R., Shapiro, E., An autonomous molecular computer for logical control of gene expression (2004) Nature, 429, pp. 423-429 Smith, A.M., Ammar, R., Nislow, C., Giaever, G., A survey of yeast genomic assays for drug and target discovery (2010) Pharmacol. Ther., 127, pp. 156-164 Bilsland, E., Pir, P., Gutteridge, A., Johns, A., King, R.D., Oliver, S.G., Functional expression of parasite drug targets and their human orthologs in yeast (2011) PLoS Negl. Trop. Dis., 10, p. e1320 Bilsland, E., Yeast-based automated highthroughput screens to identify antiparasitic lead compounds (2013) Open Biol., 3, p. 120158 Chong, C.R., Sullivan, D.J., New uses for old drugs (2007) Nature, 448, pp. 645-646 Bizer, C., Heath, T., Berners-Lee, T., Linked data - The story so far (2009) Intl. Semantic Web Info Syst., 5, pp. 1-22 Zhang, P., Nicholson, D.E., Bujnicki, J.M., Su, X., Brendle, J.J., Ferdig, M., Kyle, D.E., Chiang, P.K., Angiogenesis inhibitors specific for methionine aminopeptidase 2 as drugs for malaria and leishmaniasis (2002) J. Biomed. Sci., 9, pp. 34-40 Chen, X., Xie, S., Bhat, S., Kumar, N., Shapiro, T.A., Liu, J.O., Fumagillin and fumarranol interact with P. Falciparum methionine aminopeptidase 2 and inhibit malaria parasite growth in vitro and in vivo (2009) Chem. Biol., 16, pp. 193-201 Arico-Muendel, C., Antiparasitic activities of novel, orally available fumagillin analogs (2009) Bioorg. Med. Chem. Lett., 19, pp. 5128-5131 Leartsakulpanich, U., Imwong, M., Pukrittayakamee, S., White, N.J., Snounou, G., Sirawaraporn, W., Yuthavong, Y., Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax (2002) Mol. Biochem. Parasitol., 119, pp. 63-73 Yuthavong, Y., Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target (2012) Proc. Natl Acad. Sci. USA, 109, pp. 16823-16828 Besnard, J., Automated design of ligands to polypharmacological profiles (2012) Nature, 492, pp. 215-219